Dimension Therapeutics Announces Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
October 04, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences
August 24, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results
August 11, 2016 08:00 ET
|
Dimension Therapeutics
Ongoing Phase 1/2 trial DTX101 for hemophilia B clinical data expected later this year Lead IMD program, DTX301 for OTC deficiency, progressing toward IND filing Advancing broad inherited...
Dimension Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference
August 02, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
June 29, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Announces Recombinant DNA Advisory Committee’s Unanimous Approval of Phase 1/2 Study Protocol for DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate to Treat OTC Deficiency
June 22, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Opens New Facility in Woburn and Expands Management Team
June 21, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics to Present at Two Upcoming Investor Conferences
May 31, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Announces Presentations at the 8th European Conference on Rare Diseases & Orphan Products (ECRD)
May 27, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., May 27, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Announces Presentations at the Upcoming 21st Congress of the European Hematology Association (EHA)
May 19, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies...